Serotonin Transporter Concentrations in Women With a History of Anorexia Nervosa

NCT ID: NCT00320684

Last Updated: 2012-07-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-07-31

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will compare the concentrations of serotonin transporter in the brains of women with a history of anorexia nervosa who are currently maintaining a normal weight to those of healthy women of normal weight.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anorexia nervosa (AN) is a serious eating disorder that is associated with substantial morbidity and mortality. Despite being dangerously underweight, people with AN believe that they are overweight, and frequently exhibit symptoms of depression and anxiety. Other symptoms of AN include the following: resistance to maintaining a healthy body weight; fear of gaining weight or becoming overweight; and denial of the seriousness of one's current low body weight. Relapse rates for AN are extremely high. Serotonin is a neurotransmitter, or chemical messenger, that affects mood, impulse control, and appetite. A serotonin transporter is a specialized protein that allows cells to communicate with each other by using serotonin. Disturbances in the serotonergic system, the network of nerve cells that uses serotonin as its neurotransmitter, may contribute to the behaviors that are characteristic of AN. This study will compare women with a history of AN who are now maintaining a normal weight to healthy women of normal weight in terms of the concentration of serotonin transporter in their brains.

Participants in this observational study will undergo one positron emission tomography (PET) scan and one magnetic resonance imaging (MRI) scan. Both will be used to measure the concentration of the serotonin transporter. A radioactive tracer will be used for the PET scan, and will be administered via an intravenous catheter line. No treatment will be provided in this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Eating Disorders Anorexia Nervosa

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Women who have had anorexia nervosa but are now maintaining a healthy weight

No interventions assigned to this group

2

Women who have never had anorexia nervosa and are maintaining a healthy weight

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of anorexia nervosa
* BMI has been greater than 18.5 kg/m² for at least 9 months
* Agrees to use an effective method of contraception
* Off all psychotropic and other types of medications likely to impact the serotonin system for at least 21 days

Exclusion Criteria

* Use of any psychotropic medication or other types of medications that are likely to affect the serotonin system within 21 days of study entry
* Current DSM-IV Axis-I diagnosis of any illness other than an eating disorder
* Current AN or history of AN within 9 months prior to study entry
* Presence of any psychiatric symptom that would make participation unsafe
* Significant active physical illnesses, particularly those that may affect the brain or serotonergic system, including the following: blood dyscrasias lymphomas; hypersplenism; endocrinopathies; renal failure or chronic obstructive lung disease; autonomic neuropathies; low hemoglobin; anemia; peripheral vascular disease; and malignancy
* Currently receiving effective medication treatment for an eating disorder
* History of Raynaud's phenomena and/or acrocyanosis
* Significant regular tobacco use (defined as more than 1 pack per week)
* Lacks capacity to consent
* Pregnant
* Breastfeeding
* Any metal implants, pacemaker, metal prostheses, orthodontic appliances, or the presence of shrapnel
* Significant history of claustrophobia that would complicate the completion of MRI
* Current or past radiation exposure in the workplace or as part of a research protocol in the previous year
* Badged for radiation

Inclusion for Healthy Controls:

* Female age 18-45
* BMI \>18.5 kg/m
* Drug and medication free
* Willingness to engage in effective birth controls

Exclusion for Healthy Controls

* History of any DSM-IV Axis - I diagnosis
* History of Axis II disorder that would be accompanied by impulse control problems or significant suicidal behavior
* Significant active physical illness
* Lacks capacity to consent
* Pregnancy, currently lactating
* Metal implants, pacemaker or metal prostheses or orthodontic appliances or shrapnel
* Current, past radiation exposure in the workplace or as part of a research protocol in the previous year or badged for radiation
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

New York State Psychiatric Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Evelyn Attia, MD

Role: PRINCIPAL_INVESTIGATOR

New York State Psyciatric Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

New York State Psychiatric Institute

New York, New York, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

http://www.columbiaeatingdisorders.org

Click here for the New York State Psychiatric Institute Eating Disorders Clinic website

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K23MH002021

Identifier Type: NIH

Identifier Source: secondary_id

View Link

DATR AK-TNNS1

Identifier Type: -

Identifier Source: secondary_id

#4625/5767R

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Anorexia Nervosa and Brain in Adolescence
NCT06380257 NOT_YET_RECRUITING